Arena's olorinab improves abdominal pain in Crohn's patients in Phase IIa

Arena Pharmaceuticals Inc. (NASDSAQ:ARNA) said olorinab (APD371) significantly improved average abdominal pain score from baseline to weeks four and eight in a Phase IIa trial to treat abdominal pain in patients with Crohn’s disease.

The open-label, U.S. trial enrolled 14 patients with mild active Crohn’s disease associated with chronic abdominal pain to receive thrice-daily 25 or 100 mg oral olorinab for eight weeks. Olorinab reduced average abdominal pain score from baseline to week eight by 4.6 points at peak effect of 1.5 hours after the morning dose in 11 evaluable patients. Olorinab also led to at least a 30% improvement in average abdominal pain score in 85% of 13 evaluable patients at week four and 100% of 11 evaluable patients at week eight...